Pfizer and Innovent GLP‑1 drugs added to China’s national health‑insurance list

China’s National Healthcare Security Administration announced that Pfizer’s ecnoglutide and Innovent Biologics’ mazdutide will be covered by the state‑run health‑insurance scheme for type‑2 diabetes starting Jan. 1, 2024. The move expands the reimbursement roster that already includes products from Novo Nordisk, Eli Lilly and others. Novo Nordisk’s Ozempic sales in Greater China fell 7% in 2025, highlighting the competitive pressure of the new listings.

The inclusion should increase patient access to the two GLP‑1 drugs but may compress pricing, potentially reducing Novo Nordisk’s market share in China. The broader reimbursement list also signals continued Chinese policy support for GLP‑1 therapies, which could affect sales volumes for all listed manufacturers.

  • 1Pfizer’s ecnoglutide and Innovent’s mazdutide will be added to China’s state‑run health‑insurance scheme from Jan. 1, 2024.
  • 2The National Healthcare Security Administration issued the announcement on Nov. 14, 2026.
  • 3China’s population is about 1.4 billion people.
  • 4Sales of Novo Nordisk’s Ozempic injector pens in the greater China region slipped 7% to about 5.4 billion Danish crowns in 2025.
  • 5Other drugs added to the list include two Eli Lilly products for ulcerative colitis and Crohn’s disease and a CAR‑T therapy from JW Therapeutics.

Sources